BAFNAPHARM

Bafna Pharmaceuticals Limited has informed the Exchange regarding Resignation of Mr Kamlesh Kumar as Independent Director of the company w.e.f. May 28, 2018.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Resignation of Ms Nirmala L as Company Secretary & Compliance Officer of the company w.e.f. May 28, 2018.

Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Reconstituion of Audit Committee'.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on May 28, 2018.

Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Pursuant to the audit conducted by Medicines and Healthcare products Regulatory Agency (MHRA) our FACILITY has got RENEWAL as per the Guidelines of European Good Manufacturing Practices (EUGMP). '.

Mahaveer Chand Bafna has submitted to the Exchange a copy of disclosure under Regulation 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Bafna Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended 31-Dec-2017.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on February 12, 2018.1. Considered and approved Unaudited Financial Statements for the quarter and Nine months period ended 31st December, 2017.2. Allotment of Equity Shares on preferential basis to the share warrant holders, as the entire warrant money has been received

Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Intimation of the petition filed against the Company under Sec 9 Rule 6 of the Insolvency and Bankruptcy Code, 2016 by M/s. Encore Healthcare Private Ltd .'.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on November 10, 2017.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mrs Nirmala L as Company Secretary & Compliance Officer of the company w.e.f. November 10, 2017.

Bafna Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2017.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2017. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.

The Exchange had sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 06-Oct-2017, regarding "Outcome of Board Meeting held on October 06, 2017.". On basis of above the Company is required to clarify following: 1. Disclosure of relationships between directors (in case of appointment of a director).2. Brief profile (in case of appointment);The response of the Company is attached.

BAFNAPHARM:The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 06-Oct-2017, regarding "Outcome of Board Meeting held on October 06, 2017.". On basis of above the Company is required to clarify following: 1. Disclosure of relationships between directors (in case of appointment of a director).2. Brief profile (in case of appointment);The response of the Company is awaited.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on October 06, 2017.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2017

Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Notice of 22nd Annual General Meeting'.

Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Notice of Annual General Meeting'.

BAFNAPHARM:The Exchange had sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 12-Sep-2017, regarding " Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 08, 2017". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is attached.

BAFNAPHARM:The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 12-Sep-2017, regarding " Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 08, 2017". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.

Bafna Pharmaceuticals Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from September 24, 2017 to September 30, 2017 (both days inclusive) for the purpose of Annual General Meeting.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 08, 2017.1. Approval of Directors report2. Fixing of date, place, time of 22nd AGM.3. Fixing of Book Closure for 22nd AGM4. Fixing of Cut-off Date for voting5. To recommend the appointment of Statutory Auditor of the Company.6. To recommend the re-appointment of Managing Director of the Company 7.To recommend the re-appoint of Whole time Director of the Company.

The Exchange had sought clarification from Bafna Pharmaceuticals Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.On basis of above the Company was required to clarify the following: -1. Reconciliation of profit and loss not submitted. -2. Financial results not submitted as per Ind-AS format.The response of the Company is enclosed.

BAFNAPHARM:The Exchange had sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 08-Aug-2017, regarding " Outcome of Board Meeting held on August 08, 2017.On basis of above the Company is required to clarify following: 1. Date of appointment/cessation (as applicable) & term of appointment;The response of the Company is enclosed.

The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.On basis of above the Company is required to clarify. -1. Reconciliation of profit and loss not submitted. -2. Financial results not submitted as per Ind-AS format.The response of the Company is awaited.

BAFNAPHARM:The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 08-Aug-2017, regarding " Outcome of Board Meeting held on August 08, 2017.On basis of above the Company is required to clarify following: 1. Date of appointment/cessation (as applicable) & term of appointment;The response of the Company is awaited.

Bafna Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended June 30, 2017.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 08, 2017.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Declaration for audit reports with unmodified opinion(s).

Bafna Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2017.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 27, 2017.

Mahaveer Chand Bafna has has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Bafna Pharmaceuticals Limited has informed the Exchange that Outcome of Warrant Allotment Committee Meeting held on 18.03.2017 as per the terms of the Offer Letter.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on March 14, 2017.

Bafna Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.

Bafna Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2016.

Bafna Pharmaceuticals Limited has submitted to the Exchange a Copy of Newspaper Advertisement on Corrigendum to Postal Ballot Notice sent to the shareholders.

Bafna Pharmaceuticals Limited has submitted to the Exchange a copy of Postal Ballot Notes.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Corrigendum to Postal Ballot Notice dated January 07, 2017.

Bafna Pharmaceuticals Limited has submitted to the Exchange a copy of Calendar of Events for Postal Ballots.

Bafna Pharmaceuticals Limited has submitted to the Exchange a Copy of Postal Ballot Form and Notice.

BAFNAPHARM: The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 09-Jan-2017, informing that the Board of Directors of the Company was held on January 07, 2017, In the meeting, the following matters were decided by the Board: Considered and decided to issue 80,00,000 share warrants on preferential basis to promoter and non-promoter group at such price as may be arrived at in accordance with SEBI (ICDR) Regulations, 2009, subject to the approval of the members of the Company through Postal Ballot by way of passing a special resolution under

BAFNAPHARM:The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 09-Jan-2017, informing that the Board of Directors of the Company was held on January 07, 2017, In the meeting, the following matters were decided by the Board: Considered and decided to issue 80,00,000 share warrants on preferential basis to promoter and non-promoter group at such price as may be arrived at in accordance with SEBI (ICDR) Regulations, 2009, subject to the approval of the members of the Company through Postal Ballot by way of passing a special resolution under

Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company was held on January 07, 2017, In the meeting, the following matters were decided by the Board: Considered and decided to issue 80,00,000 share warrants on preferential basis to promoter and non-promoter group at such price as may be arrived at in accordance with SEBI (ICDR) Regulations, 2009, subject to the approval of the members of the Company through Postal Ballot by way of passing a special resolution under section 42 and 62 of the Companies Act, 2013 and other necessary approvals. It was fur

The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 05-Jan-2017, regarding "Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company was held on January 04, 2017, where it was decided to withdraw entire preferential issue of 40,00,000 share warrants and in-principle application filed with the Stock Exchanges.On basis of above the Company is required to clarify following:1. Reasons for cancellation of the same.The response of the Company is enclosed.

BAFNAPHARM:The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 05-Jan-2017, regarding "Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company was held on January 04, 2017, where it was decided to withdraw entire preferential issue of 40,00,000 share warrants and in-principle application filed with the Stock Exchanges.On basis of above the Company is required to clarify following:1. Reasons for cancellation of the same.The response of the Company is awaited.

Bafna Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company was held on January 04, 2017, where it was decided to withdraw entire preferential issue of 40,00,000 share warrants and in-principle application filed with the Stock Exchanges.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Limited Review Report for the quarter ended September 30, 2016.

BAFNAPHARM:The Exchange had sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 11-Nov-2016, regarding the Outcome of Board Meeting held on 11th November, 2016.On basis of above the Company was required to clarify following:1. Brief profile (in case of appointment);The response of the Company is attached.